CARMAT unveils interim data on autoregulation from PIVOTAL trial
Category: #health  By Pankaj Singh  Date: 2019-07-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

CARMAT unveils interim data on autoregulation from PIVOTAL trial

France-based CARMAT, the developer of the most advanced total artificial heart in the world aimed at offering therapeutic alternatives for end-stage biventricular heart failure patients, has recently released additional interim data from the PIVOTAL study in San Francisco, California, at the American Society for Artificial Internal Organs (ASAIO) Annual Conference 2019.

Citing reliable sources, CARMAT unveiled results concerning autoregulation, a unique characteristic of bioprosthesis which allows the blood flow to automatically adapt to patient requirements owing to the use of integrated sensors and intelligent control algorithms.

Apparently, all the patients in the first cohort had benefited from this autoregulation successfully, as soon as they were implanted, which led to immediate and lasting hemodynamic recovery. This provided the ideal conditions for restoration of their vital functions.

Sources mentioned that the principles and responsiveness of autoregulation need only a negligible number of adjustments, allowing doctors to concentrate on the patient’s clinical monitoring. Through a standard rehabilitation process, after being in intensive care of nearly 8 days, patients were seemingly able to leave for home within 2 months of the implant.

Reportedly, due to CARMAT prosthesis, patients could spend about 70% of their time at home enjoying a quality of life and performing usual day-to-day activities.

According to the sources, another heart transplant was performed successfully within the PIVOTAL study’s framework. This increased the number of people that have received donor hearts, post taking advantage of the support of CARMAT prosthesis for several months, to 5 patients as of now.

Within the framework of PIVOTAL study, the prosthesis has achieved a record 16 months of individual support till date, along with 6 years and 3 months of cumulative support in the total 11 patients who were implanted.

CARMAT CEO Stéphane Piat said that the positive additional results from PIVOTAL trial reinforces the confidence of the company in the capabilities of the prosthesis in providing safe, efficient solutions to patients suffering from biventricular heart failure.

Source Credits: https://www.carmatsa.com/carmat-content/uploads/2019/07/pr_carmat_asaio_en.pdf



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...